Valuation Gilead Sciences, Inc. Mexican S.E.

Stocks

End-of-day quote Mexican S.E. Other stock markets 2026-07-01			5-day change	1st Jan Change
2,217.67 ^MXN	+0.63%		0.00%	-0.21%

07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	107,677	100,942	115,118	152,281	168,630	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	10.74%	-	-
Enterprise Value (EV) ¹	118,530	126,522	118,665	131,838	169,585	178,090	168,534	158,537
Change	-	6.74%	-6.21%	11.1%	28.63%	5.02%	-5.37%	-5.93%
P/E	14.7x	23.6x	18x	243x	18.1x	-48.1x	17.6x	16.3x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	8.49x	6.74x	5.5x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.98x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.53x	5.21x	4.94x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	5.84x	5.21x	4.64x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	32.5x	9.45x	8.72x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	64.5x	10.9x	9.55x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	175x	12.7x	11.3x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	0.57%	7.85%	8.84%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.246	3.362	3.099
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.39%	2.48%	2.28%
EPS ²	4.93	3.64	4.5	0.38	6.78	-2.821	7.701	8.335
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-115%	43.7%	37.2%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,470	32,377	34,167
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	5,484	17,828	18,171
EBIT ¹	12,548	12,180	10,484	8,520	13,193	2,760	15,503	16,606
Net income ¹	6,225	4,592	5,665	480	8,510	-3,373	9,548	10,218
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	9,460	-96.43	-10,093
Reference price ²	72.61	85.85	81.01	92.37	122.74	135.82	135.82	135.82
Nbr of stocks (in thousands)	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,241,570	-	-
Announcement Date	2/1/22	2/2/23	2/6/24	2/11/25	2/10/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	35.46x	12.91x	26.29x	0.56%	1,084B
JOHNSON & JOHNSON	28.11x	6.45x	17.52x	2.03%	634B
ABBVIE INC.	30.45x	7.46x	15.28x	2.72%	447B
ROCHE HOLDING AG	17.81x	4.43x	10.97x	2.99%	330B
ASTRAZENECA PLC	23.78x	4.98x	13.89x	1.75%	295B
NOVARTIS AG	21.66x	5.57x	13.46x	2.83%	285B
NOVO NORDISK A/S	14.26x	5.31x	10.9x	3.51%	218B
AMGEN INC.	24.07x	6.37x	11.22x	2.74%	199B
PFIZER INC.	11.77x	3.02x	7.45x	7.28%	137B
Average	23.04x	6.28x	14.11x	2.94%	403.15B
Weighted average by Cap.	27.13x	7.93x	17.53x	2.13%